替吉奥联合奥沙利铂治疗进展期胃癌安全性评价

Safety Evaluation of TS-1 plus Oxaliplatin in the Treatment for Advanced Gastric Cancer

[目的]评价替吉奥联合奥沙利铂治疗进展期胃癌的临床疗效和安全性。[方法]采用随机对照法,将36例进展期胃癌患者随机分为替吉奥联合奥沙利铂组(18例)和FOLFOX4组(18例),至少行2个周期化疗后评价疗效与不良反应。[结果]36例患者均可评价疗效,替吉奥联合奥沙利铂组CR1例(5.6%),PR7例(38.9%),SD6例(33.3%),PD4例(22.2%),有效率44.5%;FOLFOX4组PR6例(33.3%),SD10例(55.5%),PD2例(11.1%),有效率33.3%;两组有效率比较差异无统计学意义(χ2=0.808,P=0.369)。两组主要不良反应为血液学毒性、胃肠道反应和神经系统毒性,其中FOLFOX4组恶心呕吐发生率显著高于替吉奥联合奥沙利铂组(χ2=4.485,P=0.034)。[结论]替吉奥联合奥沙利铂方案治疗进展期胃癌疗效与FOLFOX4方案相当,但耐受性较好。

[Purpose] To evaluate the efficacy and safety of TS-1 plus oxaliplatin in the treatment of patients with advanced gastric cancer.[Methods]Thirty-six cases with advanced gastric cancer were randomly divided into TS-1 plus oxaliplatin group （n=18） and FOLFOX4 group （n=18）.The efficacy and toxicity were evaluated after at least two cycles of chemotherapy.[Results] Response was evaluable in all patients.Of 18 cases in TS-1 plus oxaliplatin group,1 case in CR（5.6%）,7 cases in PR（38.9%）,6 cases in SD （33.3%） and 4 cases in PD（22.2%） were found with response rate of 44.5%.Of 18 cases in FOLFOX4 group,6 cases in PR（33.3%）,10 cases in SD（55.5%） and 2 cases in PD（11.1%） were found with response rate of 33.3%.There was no significant difference with response between the two groups（χ2=0.808,P=0.369） .The main toxicity in both groups was hematological toxicity,gastrointestinal reaction and nervous system toxicity.The incidence of nausea and vomiting in FOLFOX4 group was higher than that in TS-1 plus oxaliplatin group（χ2=4.485,P=0.034）.[Conclusion] The response of TS-1 plus oxaliplatin regimen and FOLFOX4 regimen for advanced gastric cancer is similar,and the toxicity of TS-1 plus oxaliplatin regimen is tolerable.